{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:44:44Z","timestamp":1783683884646,"version":"3.55.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:00:00Z","timestamp":1585008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"National Natural Science Foundation of the Peoples\u2019 Republic of China","award":["81402463"],"award-info":[{"award-number":["81402463"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-1-001"],"award-info":[{"award-number":["2016-I2M-1-001"]}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["2016-I2M-3-005"],"award-info":[{"award-number":["2016-I2M-3-005"]}]},{"name":"Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences","award":["2016ZX310178"],"award-info":[{"award-number":["2016ZX310178"]}]},{"name":"Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences","award":["2018PT32012"],"award-info":[{"award-number":["2018PT32012"]}]},{"name":"Non-profit Central Research Institute Fund of the Chinese Academy of Medical Sciences","award":["2017PT32001"],"award-info":[{"award-number":["2017PT32001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Despite great progress in surgery and other treatments, the prognosis of patients with esophageal squamous cell carcinoma (ESCC) is still very poor. HER2 has strong therapeutic implications in certain cancers, such as breast cancer and gastric cancer. However, literature on the frequency of HER2 expression in ESCC is scarce. In the present study, HER2 protein expression, HER2 gene amplification and the relationship between HER2 status and clinicopathological characteristics were evaluated in a large cohort of Chinese ESCC patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 857 consecutive ESCC patients who received radical esophagectomy without neoadjuvant therapy between January 2014 and October 2015 were included in this retrospective study. HER2 protein expression was analyzed by immunohistochemistry (IHC), and its correlation with clinicopathological parameters was assessed. In addition, 65 cases, including 13 HER2 overexpression (3+) cases and 52 HER2 equivocal (2+) cases from the 857-case cohort, and another 104 ESCC cases, including 1 HER2 overexpression (3+) case, 3 HER2 equivocal (2+) cases and 100 HER2 negative (1+\/0) cases, were selected to construct tissue microarrays (TMAs). Dual-color in situ hybridization (DISH) was performed on the TMAs to assess HER2 gene amplification and the relationship with clinicopathological parameters.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found HER2 overexpression (3+) status in 1.5% (13\/857) of cases and HER2 equivocal (2+) status in 6.1% (52\/857) of cases. HER2 IHC expression was significantly associated with gender (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.028). However, there were no significant correlations between HER2 IHC expression and age, tumor differentiation, pT stage, pN stage, pM stage and pTNM stage (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05). Regarding the 169 cases analyzed by DISH, 14 (of 14, 100%) HER2 overexpression (3+) cases, 10 (of 55, 18.2%) HER2 equivocal (2+) cases, and 0 (of 100, 0%) HER2 negative (1+\/0) cases showed HER2 gene amplification. HER2 gene amplification was not significantly associated with clinicopathological characteristics such as age, gender, tumor differentiation, pT stage, pN stage, pM stage and pTNM stage (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&gt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Approximately 1.5% of the Chinese ESCC patients had HER2 overexpression based on IHC. IHC and DISH had a high concordance rate. These results provide valuable insight for the future treatment of ESCC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13000-020-00950-y","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T06:06:44Z","timestamp":1585030004000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["HER2 expression and relevant clinicopathological features in esophageal squamous cell carcinoma in a Chinese population"],"prefix":"10.1186","volume":"15","author":[{"given":"Lulu","family":"Rong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuyun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,24]]},"reference":[{"key":"950_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.3322\/caac.21262","volume":"65","author":"LA Torre","year":"2015","unstructured":"Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87\u2013108. https:\/\/doi.org\/10.3322\/caac.21262.","journal-title":"CA Cancer J Clin"},{"key":"950_CR2","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1186\/1471-2407-12-569","volume":"12","author":"IM Gonzaga","year":"2012","unstructured":"Gonzaga IM, Soareslima SC, de Santos PT, Blanco TC, de Reis BS. Alterations in epidermal growth factor receptors 1 and 2 in esophageal squamous cell carcinomas. BMC Cancer. 2012;12:569. https:\/\/doi.org\/10.1186\/1471-2407-12-569.","journal-title":"BMC Cancer"},{"key":"950_CR3","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1007\/s00109-014-1187-5","volume":"92","author":"CD Fichter","year":"2014","unstructured":"Fichter CD, Gudernatsch V, Przypadlo CM, Follo M, Schmidt G, Werner M, et al. ErbB targeting inhibitors repress cell migration of esophageal squamous cell carcinoma and adenocarcinoma cells by distinct signaling pathways. J Mol Med (Berl). 2014;92:1209\u201323. https:\/\/doi.org\/10.1007\/s00109-014-1187-5.","journal-title":"J Mol Med (Berl)"},{"key":"950_CR4","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/1746-1596-8-76","volume":"8","author":"L Shan","year":"2013","unstructured":"Shan L, Ying J, Lu N. HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population. Diagn Pathol. 2013;8:76. https:\/\/doi.org\/10.1186\/1746-1596-8-76.","journal-title":"Diagn Pathol"},{"key":"950_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1007\/s12032-011-9850-y","volume":"29","author":"N Zhan","year":"2012","unstructured":"Zhan N, Dong W, Tang Y, Wang Z, Xiong C. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012;29:933\u201340. https:\/\/doi.org\/10.1007\/s12032-011-9850-y.","journal-title":"Med Oncol"},{"key":"950_CR6","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1038\/sj.bjc.6602499","volume":"92","author":"K Mimura","year":"2005","unstructured":"Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2\/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92:1253\u201360. https:\/\/doi.org\/10.1038\/sj.bjc.6602499.","journal-title":"Br J Cancer"},{"key":"950_CR7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1471-2407-9-6","volume":"9","author":"Y Sato-Kuwabara","year":"2009","unstructured":"Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2\/neu in esophageal squamous cell carcinoma using fluorescence in situ hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009;9:6. https:\/\/doi.org\/10.1186\/1471-2407-9-6.","journal-title":"BMC Cancer"},{"key":"950_CR8","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3322\/caac.21399","volume":"67","author":"TW Rice","year":"2017","unstructured":"Rice TW, Gress DM, Patil DT, Hofstetter WL, Kelsen DP, Blackstone EH. Cancer of the esophagus and esophagogastric junction-major changes in the American joint committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67:304\u201317. https:\/\/doi.org\/10.3322\/caac.21399.","journal-title":"CA Cancer J Clin"},{"key":"950_CR9","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","volume":"31","author":"AC Wolff","year":"2013","unstructured":"Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997\u20134013. https:\/\/doi.org\/10.1200\/JCO.2013.50.9984.","journal-title":"J Clin Oncol"},{"key":"950_CR10","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1111\/j.1442-2050.2006.00570.x","volume":"19","author":"M Dreilich","year":"2006","unstructured":"Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19:224\u201331. https:\/\/doi.org\/10.1111\/j.1442-2050.2006.00570.x.","journal-title":"Dis Esophagus"},{"key":"950_CR11","first-page":"4975","volume":"33","author":"AMK Nig","year":"2013","unstructured":"Nig AMK, Reeh M, Dancau A, Rathjens M, Gros S. Concordance of HER2 status in primary tumour and lymph node metastases in patients with esophageal carcinoma. Anticancer Res. 2013;33:4975\u201382.","journal-title":"Anticancer Res"},{"key":"950_CR12","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/sj.bjc.6603885","volume":"97","author":"Y Kawaguchi","year":"2007","unstructured":"Kawaguchi Y, Kono K, Mimura K, Mitsui F, Sugai H, Akaike H, et al. Targeting EGFR and HER-2 with cetuximab- and trastuzumab-mediated immunotherapy in oesophageal squamous cell carcinoma. Br J Cancer. 2007;97:494\u2013501. https:\/\/doi.org\/10.1038\/sj.bjc.6603885.","journal-title":"Br J Cancer"},{"key":"950_CR13","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1097\/PAS.0b013e3181f8be17","volume":"34","author":"SF Schoppmann","year":"2010","unstructured":"Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34:1868\u201373. https:\/\/doi.org\/10.1097\/PAS.0b013e3181f8be17.","journal-title":"Am J Surg Pathol"},{"key":"950_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/sj.bjc.6602625","volume":"93","author":"L Gibault","year":"2005","unstructured":"Gibault L, Metges JP, Conan-Charlet V, Lozac'H P, Robaszkiewicz M, Bessaguet C, et al. Diffuse EGFR staining is associated with reduced overall survival in locally advanced oesophageal squamous cell cancer. Br J Cancer. 2005;93:107\u201315. https:\/\/doi.org\/10.1038\/sj.bjc.6602625.","journal-title":"Br J Cancer"},{"key":"950_CR15","doi-asserted-by":"publisher","first-page":"2351","DOI":"10.1007\/s00432-017-2482-7","volume":"143","author":"K Hatogai","year":"2017","unstructured":"Hatogai K, Fujii S, Kojima T, Daiko H, Nomura S, Doi T, et al. Large-scale comprehensive immunohistochemical biomarker analyses in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2017;143:2351\u201361. https:\/\/doi.org\/10.1007\/s00432-017-2482-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"950_CR16","doi-asserted-by":"publisher","first-page":"903","DOI":"10.3892\/ol.2013.1130","volume":"5","author":"S Shibata-Kobayashi","year":"2013","unstructured":"Shibata-Kobayashi S, Yamashita H, Okuma K, Shiraishi K, Igaki H, Ohtomo K, et al. Correlation among 16 biological factors [p53, p21(waf1), MIB-1 (Ki-67), p16(INK4A), cyclin D1, E-cadherin, Bcl-2, TNF-alpha, NF-kappaB, TGF-beta, MMP-7, COX-2, EGFR, HER2\/neu, ER, and HIF-1alpha] and clinical outcomes following curative chemoradiation therapy in 10 patients with esophageal squamous cell carcinoma. Oncol Lett. 2013;5:903\u201310. https:\/\/doi.org\/10.3892\/ol.2013.1130.","journal-title":"Oncol Lett"},{"key":"950_CR17","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/s0360-3016(03)00782-x","volume":"57","author":"M Akamatsu","year":"2003","unstructured":"Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;57:1323\u20137. https:\/\/doi.org\/10.1016\/s0360-3016(03)00782-x.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"950_CR18","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2016.69.4836","volume":"35","author":"AN Bartley","year":"2017","unstructured":"Bartley AN, Washington MK, Colasacco C, Ventura CB, Ismaila N, Benson AR, et al. HER2 testing and clinical decision making in Gastroesophageal adenocarcinoma: guideline from the College of American Pathologists, American Society for Clinical Pathology, and the American Society of Clinical Oncology. J Clin Oncol. 2017;35:446\u201364. https:\/\/doi.org\/10.1200\/JCO.2016.69.4836.","journal-title":"J Clin Oncol"},{"key":"950_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.3892\/ol.2015.3975","volume":"11","author":"Y Chen","year":"2016","unstructured":"Chen Y, Zhu S, Xu X, Zhao AN, Hu J. Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma. Oncol Lett. 2016;11:745\u201352. https:\/\/doi.org\/10.3892\/ol.2015.3975.","journal-title":"Oncol Lett"},{"key":"950_CR20","doi-asserted-by":"publisher","first-page":"516","DOI":"10.5858\/arpa.2017-0039-OA","volume":"142","author":"L Fazlollahi","year":"2018","unstructured":"Fazlollahi L, Remotti HE, Iuga A, Yang HM, Lagana SM, Sepulveda AR. HER2 heterogeneity in Gastroesophageal Cancer detected by testing biopsy and resection specimens. Arch Pathol Lab Med. 2018;142:516\u201322. https:\/\/doi.org\/10.5858\/arpa.2017-0039-OA.","journal-title":"Arch Pathol Lab Med"},{"key":"950_CR21","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00432-004-0610-7","volume":"131","author":"P Sunpaweravong","year":"2005","unstructured":"Sunpaweravong P, Sunpaweravong S, Puttawibul P, Mitarnun W, Zeng C, Baron AE, et al. Epidermal growth factor receptor and cyclin D1 are independently amplified and overexpressed in esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2005;131:111\u20139. https:\/\/doi.org\/10.1007\/s00432-004-0610-7.","journal-title":"J Cancer Res Clin Oncol"},{"key":"950_CR22","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1007\/s12282-012-0436-0","volume":"21","author":"R Horii","year":"2014","unstructured":"Horii R, Matsuura M, Iwase T, Ito Y, Akiyama F. Comparison of dual-color in-situ hybridization and fluorescence in-situ hybridization in HER2 gene amplification in breast cancer. Breast Cancer. 2014;21:598\u2013604. https:\/\/doi.org\/10.1007\/s12282-012-0436-0.","journal-title":"Breast Cancer"},{"key":"950_CR23","doi-asserted-by":"publisher","first-page":"7926","DOI":"10.3748\/wjg.v22.i35.7926","volume":"22","author":"N Fusco","year":"2016","unstructured":"Fusco N, Bosari S. HER2 aberrations and heterogeneity in cancers of the digestive system: implications for pathologists and gastroenterologists. World J Gastroenterol. 2016;22:7926\u201337. https:\/\/doi.org\/10.3748\/wjg.v22.i35.7926.","journal-title":"World J Gastroenterol"},{"key":"950_CR24","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/PAP.0000000000000015","volume":"21","author":"U Krishnamurti","year":"2014","unstructured":"Krishnamurti U, Silverman JF. HER2 in breast cancer: a review and update. Adv Anat Pathol. 2014;21:100\u20137. https:\/\/doi.org\/10.1097\/PAP.0000000000000015.","journal-title":"Adv Anat Pathol"},{"key":"950_CR25","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast Cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018;36:2105\u201322. https:\/\/doi.org\/10.1200\/JCO.2018.77.8738.","journal-title":"J Clin Oncol"},{"key":"950_CR26","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397. https:\/\/doi.org\/10.1016\/S0140-6736(10)61121-X.","journal-title":"Lancet."},{"key":"950_CR27","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.ejca.2014.01.009","volume":"50","author":"S Kasper","year":"2014","unstructured":"Kasper S, Schuler M. Targeted therapies in gastroesophageal cancer. Eur J Cancer. 2014;50:1247\u201358. https:\/\/doi.org\/10.1016\/j.ejca.2014.01.009.","journal-title":"Eur J Cancer"},{"key":"950_CR28","first-page":"1918","volume":"38","author":"K Mimura","year":"2011","unstructured":"Mimura K, Izawa S, Siba S, Maruyama T, Watanabe M, Kawaguchi Y, et al. The effect of immune-based therapy with cytotoxic T lymphocyte and molecular targeting therapy for HER2 in esophageal squamous cell carcinoma. Gan To Kagaku Ryoho. 2011;38:1918\u201320.","journal-title":"Gan To Kagaku Ryoho"},{"key":"950_CR29","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1586\/17474124.2016.1140036","volume":"10","author":"L Zhang","year":"2016","unstructured":"Zhang L, Ma J, Han Y, Liu J, Zhou W, Hong L, et al. Targeted therapy in esophageal cancer. Expert Rev Gastroenterol Hepatol. 2016;10:595\u2013604. https:\/\/doi.org\/10.1586\/17474124.2016.1140036.","journal-title":"Expert Rev Gastroenterol Hepatol"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13000-020-00950-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-020-00950-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T20:23:21Z","timestamp":1616531001000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-020-00950-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,24]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["950"],"URL":"https:\/\/doi.org\/10.1186\/s13000-020-00950-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.13291\/v1","asserted-by":"object"}]},"ISSN":["1746-1596"],"issn-type":[{"value":"1746-1596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,24]]},"assertion":[{"value":"25 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted after approval by the Ethics Committee from the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. Consent was not required from each patient because this was a retrospective study. Tumor tissues for this study were obtained from the archival paraffin blocks of the repository of the Department of Pathology, National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College. All procedures were performed in line with the 1983 version of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}